Matrixx Initiatives, Inc. Investor Investigations allege possible securities laws violations
Posted by Trevor Allen
Monday, 13 July 2009
Investigations on behalf of investors of Matrixx Initiatives, Inc. (Public, NASDAQ:MTXX) over possible Securities Laws Violations by Matrixx Initiatives – Contact the Shareholders Foundation, Inc at mail@shareholdersfoundation.com
SAN DIEGO, CA (Shareholders Foundation) - Matrixx Initiatives, Inc. has recalled its Zicam nasal products as investigations on behalf of certain investors in Matrixx Initiatives, Inc. (Public, NASDAQ:MTXX) over possible securities fraud by Matrixx Initiatives, Inc. announced.
Those who purchased shares of Matrixx Initiatives, Inc. (NASDAQ:MTXX) since December 2007 and /or are aware of any facts relating to this investigation or can assist this investigation, you should contact the Shareholders Foundation, Inc at:
Email: mail@shareholdersfoundation.comThis e-mail address is being protected from spam bots, you need JavaScript enabled to view it
Or call us at: +1 (858) 779 - 1554
According to the investigations by law firms the investigations focus on securities laws violations by Matrixx Initiatives. Matrixx Initiatives, Inc. has recalled its Zicam nasal products, but Matrixx Initiatives, Inc. has been investigated by the SEC with respect to its marketing practices, and according to the investigation it is believed that information surrounding the Zicam line of products, as well as Matrixx Initiatives liability in connection with these products, was not reaching Matrixx's shareholders. On June 13, the FDA advised consumers to stop using three Matrixx-manufactured over-the-counter cold remedy products marketed under the Zicam name because they are associated with the loss of smell, which may be long-lasting and permanent.
According to one law firm, it is investigating reports of possible securities law violations by Matrixx Initiatives, Inc. (Nasdaq: MTXX), over the drug maker’s reported failure to provide the Food and Drug Administration (FDA) with more than 800 reports relating to the loss of sense of smell associated with the Zicam Cold Remedy intranasal products.
According to the FDA, as of Dec. 2007, Matrixx Initiatives was required to provide reports of adverse reactions to the agency per the Dietary Supplement and Nonprescription Drug Consumer Protection Act. On June 16, 2009 Matrixx Initiatives announced that it has received a Warning Letter from the Food and Drug Administration (the FDA). The FDA has asserted that Matrixx Initiatives is in violation of its regulations by failing to file a new drug application for its Zicam Cold Remedy Nasal Gel and Zicam Cold Remedy Gel Swabs and that those products are misbranded under their regulations for failing to adequately warn of risks. The FDA informed Matrixx Initiatives it concluded that certain Zicam products may pose serious risks to consumers who use them, and that Matrixx marketing practices violate several laws relating to the products, so the investigation. Matrixx Initiatives stated in its press release that “Since Zicam Cold Remedy intranasal Cold Remedy products were first introduced in the market in 1999, more than 35 million retail units representing over 1 billion doses have been sold “ and it “believes these products are safe and do not cause anosmia”, but then announced in a second press release on the same day that “Matrixx Initiatives Voluntarily Withdraws Zicam Cold Remedy Swabs, Zicam Cold Remedy Nasal Gel” as “Consumer safety is and has always been the company's top priority”. Then on June 22, 2009 nearly 120 individual claims were filed in Arizona Superior Court against Matrixx Initiatives on behalf of individuals from 32 states, from Hawaii to a U.S. contractor in Afghanistan, as well as for a dozen Arizona residents who reported side effects ranging from a complete loss of smell and taste, to diminished senses of smell. The FDA stated in its letter from June 16, 2009 that the "agency is aware that Matrixx appears to have more than 800 reports related to loss of sense of smell associated with Zicam Cold Remedy intranasal products" and directed Matrixx ”to arrange submission of all reports related to loss of sense of smell associated with Zicam Cold Remedy intranasal products" and to "indicate which of these reports have been previously submitted to the FDA." Upon release of this letter by the FDA, so the investigation, Matrixx Initiatives stock (NASDAQ: MTXX) declined from approximately $19 per share to less than $7 per share. On July 23, 2009, Matrixx Initiatives acknowledged the Securities and Exchange Commission is launching an informal inquiry. Since December 2007, insiders, including the Executive VP and CFO, the VP of Sales and the VP of Research and Development, have sold more than $2.7 million worth of Matrixx shares, so the investigation.
Matrixx Initiatives, Inc. is located in Phoenix, Arizona . It develops, produces, markets and sells over-the-counter (OTC) healthcare products with an emphasis on those that utilize delivery systems that provide consumers with
Better Ways
to Get Better. Through its subsidiary, Zicam, LLC, the Company markets and sells products under the Zicam brand. Shares of Matrixx Initiatives, Inc. (NASDAQ:MTXX) continued to decline on Monday, July 06, 2009, and closed at $6.05 per share, down from a 52weekHigh of $19.74 per share, and over $21.50 per share in 2007. Matrixx Initiatives, Inc. reported Total Revenue of $100.97million and a net income of $10.43million in 2007 and $111.63million and a net income of $13.86million in 2008.
Those who purchased shares of Matrixx Initiatives, Inc. (NASDAQ:MTXX) since December 2007 and /or are aware of any facts relating to this investigation or can assist this investigation, should contact the Shareholders Foundation, Inc at:
Email: mail@shareholdersfoundation.comThis e-mail address is being protected from spam bots, you need JavaScript enabled to view it
Or call us at: +1 (858) 779 - 1554
Shareholders Foundation, Inc.
Trevor Allen
3111 Camino Del Rio North - Suite 423 -
92108 San Diego
Tel:+1-(858)-779-1554
Fax:+1-(858)-605-5739
mail@shareholdersfoundation.comThis e-mail address is being protected from spam bots, you need JavaScript enabled to view it
www.ShareholdersFoundation.com
_____________________________________________________________________________________
Advertising. The Shareholders Foundation, Inc. is an investor advocacy group. We do research related to shareholder issues and inform investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. At Shareholders Foundation, Inc. we are in contact with a large number of shareholders. We believe that together we can combine the interests of many investors, and use the size of our interest as leverage against the giant corporations. We offer help, support, and assistance for every shareholder. We help investors find answers to their questions and equitable solutions to their problems. The Shareholders Foundation, Inc. is not a law firm. Any statements made in press releases, emails or over the phone by any member or personnel employed by Shareholders Foundation, Inc. or by third parties related to the Shareholders Foundation, Inc. is provided for research and guidance purposes only and are not legal advices, as we can not give you legal advice. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
|
